Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model

Journal of Bone and Mineral Research

Volumn 19, Issue 12, 2004, Pages 2021-2032

  Zhu, Wei ^a   Rawlins, Bernard A ^a   Boachie Adjei, Oheneba ^a   Myers, Elizabeth R ^a   Arimizu, Jun ^a   Choi, Eugene ^a   Lieberman, Jay R ^b   Crystal, Ronald G ^c   Hidaka, Chisa ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bone; Bone mineralization; Bone morphogenetic protein; Osteoblasts; Rodent

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; DIMER; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; BMP2 PROTEIN, HUMAN; BMP2 PROTEIN, MOUSE; BMP2 PROTEIN, RAT; BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE RADIOGRAPHY; CELL DIFFERENTIATION; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LOW DRUG DOSE; MOUSE; MYOBLAST; NONHUMAN; OSSIFICATION; POSTOPERATIVE PERIOD; PRECIPITATION; PROTEIN EXPRESSION; SPINE FUSION; STATISTICAL SIGNIFICANCE; SUPERNATANT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BONE; BONE DEVELOPMENT; CELL STRAIN 3T3; CYTOLOGY; DIMERIZATION; DOSE RESPONSE; EPITHELIUM CELL; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; OSTEOBLAST; PHYSIOLOGY; RAT; TIME; TUMOR CELL LINE;

3T3 CELLS; ADENOVIRIDAE; ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; OSTEOBLASTS; OSTEOGENESIS; RATS; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 21344464386     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040821     Document Type: Article

References (73)

1. Urist MR 1965 Bone: Formation by autoinduction. Science 150:893-899.
2. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, Sibley BS, Wozney JM 1988 Purification and characterization of other distinct bone-inducins factors. Proc Natl Acad Sci USA 85:9484-9488.
3. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA 1988 Novel regulators of bone formation: Molecular clones and activities. Science 242:1528-1534.
4. Sampath TK, Coughlin JE, Whetstone RM, Banach D, Corbett C, Ridge RJ, Ozkaynak E, Oppermann H, Rueger DC 1990 Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem 265:13198-13205.
5. Ozkaynak E, Rueger DC, Drier EA, Corbett C, Ridge RJ, Sampath TK, Oppermann H 1990 OP-1 cDNA encodes an osteogenic protein in the TGF-beta family. EMBO J 9:2085-2093.
6. Lyons KM, Hogan BL, Robertson EJ 1995 Colocalization of BMP 7 and BMP 2 RNAs suggests that these factors cooperatively mediate tissue interactions during murine development. Mech Dev 50:71-83.
7. Katagiri T, Boorla S, Frendo JL, Hogan BL, Karsenty G 1998 Skeletal abnormalities in doubly heterozygous Bmp4 and Bmp7 mice. Dev Genet 22:340-348.
8. Solloway MJ, Robertson EJ 1999 Early embryonic lethality in Bmp5;Bmp7 double mutant mice suggests functional redundancy within the 60A subgroup. Development 126:1753-1768.
9. Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, Sasaki S, Fujisawa Y 1995 Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210:670-677.
10. Hazama M, Aono A, Ueno N, Fujisawa Y 1995 Efficient expression of a heterodimer of bone morphogenetic protein subunits using a baculovirus expression system. Biochem Biophys Res Commun 209:859-866.
11. Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA, Wozney JM 1996 Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13:291-300.
12. Boden SD, Martin GJ, Morone MA, Ugbo JL, Moskovitz PA 1999 Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 24:1179-1185.
13. Glazer PA, Spencer UM, Alkalay RN, Schwardt J 2001 In vivo evaluation of calcium sulfate as a bone graft substitute for lumbar spinal fusion. Spine J 1:395-401.
14. Kimura I, Shingu H, Murata M, Hashiguchi H 2001 Lumbar posterolateral fusion alone or with transpedicular instrumentation in L4-L5 degenerative spondylolisthesis. J Spinal Disord Tech 14:301-310.
15. Fischgrund JS 2004 An argument for instrumented posterolateral fusion for patients with degenerative spondylolisthesis and spinal stenosis. Spine 29:173-174.
16. Lauerman WC, Bradford DS, Transfeldt EE, Ogilvie JW 1991 Management of pseudarthrosis after arthrodesis of the spine for idiopathic scoliosis. J Bone Joint Surg Am 73:222-236.
17. Cummine JL, Lonstein JE, Moe JH, Winter RB, Bradford DS 1979 Reconstructive surgery in the adult for failed scoliosis fusion. J Bone Joint Surg Am 61:1151-1160.
18. Boden SD, Kang J, Sandhu H, Heller JG 2002 Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: A prospective, randomized clinical pilot trial. 2002 Volvo Award in clinical studies. Spine 27:2662-2673.
19. Lund T, Nydegger T, Rathonyi G, Nolle LP, Schlenzka D, Oxland TR 2003 Three-dimensional stabilization provided by the external spinal fixator compared to two internal fixation devices: A biomechanical in vitro flexibility study. Eur Spine J 12:474-479.
20. Shikinami Y, Okuno M 2003 Mechanical evaluation of novel spinal interbody fusion cages made of bioactive, resorbable composites. Biomaterials 24:3161-3170.
21. Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA 1996 Complications of iliac crest bone graft harvesting. Clin Orthop 329:300-309.
22. Kurz LT, Garfin SR, Booth RE 1989 Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine 14:1324-1331.
23. Younger EM, Chapman MW 1989 Morbidity at bone graft donor sites. J Orthop Trauma 3:192-195.
24. An HS, Lynch K, Toth J 1995 Prospective comparison of autograft vs. allograft for adult posterolateral lumbar spine fusion: Differences among freeze-dried, frozen, and mixed grafts. J Spinal Disord Tech 8:131-135.
25. Buttermann GR, Glazer PA, Bradford DS 1996 The use of bone allografts in the spine. Clin Orthop 3:75-85.
26. Ehrler DM, Vaccaro AR 2000 The use of allograft bone in lumbar spine surgery. Clin Orthop 371:38-45.
27. Sandhu HS, Grewal HS, Parvataneni H 1999 Bone grafting for spinal fusion. Orthop Clin North Am 30:685-698.
28. Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wozney JM 1990 Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87:9843-9847.
29. Cook SD 1999 Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. Orthopedics 22:669-671.
30. Friedlaender GE 2001 OP-1 clinical studies. J Bone Joint Surg Am 83(Suppl 1):S160-S161.
31. Sandhu HS, Khan SN 2002 Animal models for preclinical assessment of bone morphogenetic proteins in the spine. Spine 27(Suppl 16):S32-S38.
32. Schmitt JM, Hwang K, Winn SR, Hollinger JO 1999 Bone morphogenetic proteins: An update on basic biology and clinical relevance. J Orthop Res 17:269-278.
33. Wozney JM 2002 Overview of bone morphogenetic proteins. Spine 27(Suppl 16):S2-S8.
34. Zlotolow DA, Vaccaro AR, Salamon ML, Albert TJ 2000 The role of human bone morphogenetic proteins in spinal fusion. J Am Acad Orthop Surg 8:3-9.
35. Kaneko H, Arakawa Y, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, Hakeda Y 2000 Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27:479-486.
36. Panchision DM, Pickel JM, Studer L, Lee SH, Turner PA, Hazel TG, McKay RD 2001 Sequential actions of BMP receptors control neural precursor cell production and fate. Genes Dev 15:2094-2110.
37. Hidaka C, Goshi K, Rawlins B, Boachie-Adjei O, Crystal RG 2003 Enhancement of Spine fusion using combined gene therapy and tissue engineering: BMP-7 expressing bone marrow cells and allograft bone. Spine 28:2049-2057.
38. Wang JC, Kanim LE, Yoo S, Campbell PA, Berk AJ, Lieberman JR 2003 Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Bone Joint Surg Am 85:905-911.
39. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GA, Berk AJ, Witte ON 1999 The effect of regional gene therapy with bone morphogenetic protein-2-prodicing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81:905-917.
40. Hersh J, Crystal RG, Bewig B 1995 Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther 2:124-131.
41. Mittereder N, March KL, Trapnell BC 1996 Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-509.
42. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L 1992 In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155.
43. Breitbart AS, Grande DA, Mason JM, Barcia M, James T, Grant RT 1999 Gene-enhanced tissue engineering: Applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg 42:488-495.
44. Boden SD, Schimandle JH, Hutton WC 1995 An experimental lumbar intertransverse process spinal fusion model. Radiographic, histologic, and biomechanical healing characteristics. Spine 20:412-420.
45. Boden SD, Schimandle JH, Hutton WC 1995 Volvo Award in basic sciences. The use of an osteoinductive growth factor for lumbar spinal fusion. Part H: Study of dose, carrier, and species. Spine 20:2633-2644.
46. Viggeswarapu M, Boden SD, Liu Y, Hair GA, Louis-Ugbo J, Murakami H, Kim HS, Mayr MT, Hutton WC, Titus L 2001 Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J Bone Joint Surg Am 83:364-376.
47. Suh DY, Boden SD, Louis-Ugbo J, Mayr M, Murakami H, Kim HS, Minamide A, Hutton WC 2002 Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine 27:353-360.
48. Akamaru T, Suh D, Boden SD, Kim HS, Minamide A, Louis-Ugbo J 2003 Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 28:429-434.
49. Jahng TA, Fu TS, Cunningham BW, Dmitriev AE, Kim DH 2004 Endoscopic instrumented posterolateral lumbar fusion with Healos and recombinant human growth/differentiation factor-5. Neurosurgery 54:171-181.
50. Eriksen EF, Axelord DW, Melsen F 1994 Bone histology and histomorphometry. In: Erikse EF, Axelord, DW, Melsen F (eds.) Bone Histomorphometry. Raven Press, New York, NY, USA, pp. 33-48.
51. Aoki H, Fujii M, Imamura T, Yagi K, Takehara K, Kato M, Miyazono K 2001 Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci 114:1483-1489.
52. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T 1994 Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127:1755-1766.
53. Yeh LC, Tsai AD, Lee JC 2002 Osteogenic protein-1 (OP-1, BMP-7) induces osteoblastic cell differentiation of the pluripotent mesenchymal cell line C2C12. J Cell Biochem 87:292-304.
54. Fujii M, Takeda K, Imamura T, Aoki H, Sampath TK, Enomoto S, Kawabata M, Kato M, Ichijo H, Miyazono K 1999 Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 10:3801-3813.
55. Hackett NR, El Sawy T, Lee LY, Silva I, O'Leary J, Rosengart TK, Crystal RG 2000 Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther 2:649-656.
56. Hidaka C, Goodrich LR, Chen CT, Warren RF, Crystal RG, Nixon AJ 2003 Acceleration of cartilage repair by genetically modified chondrocytes over expressing bone morphogenetic protein-7. J Orthop Res 21:573-583.
57. Muschler GF, Nitto H, Matsukura Y, Boehm C, Valdevit A, Kambic H, Davros W, Powell K, Easley K 2003 Spine fusion using cell matrix composites enriched in bone marrow-derived cells. Clin Orthop 407:102-118.
58. Cui Q, Ming Xiao Z, Balian G, Wang GJ 2001 Comparison of lumbar spine fusion using mixed and cloned marrow cells. Spine 26:2305-2310.
59. Cheng SL, Lou J, Wright NM, Lai CF, Avioli LV, Riew KD 2001 In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif Tissue Int 68:87-94.
60. Helm GA, Alden TD, Beres EJ, Hudson SB, Das S, Engh JA, Pittman DD, Kerns KM, Kallmes DF 2000 Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 92(Suppl 2):191-196.
61. Liu Q, Muruve DA 2003 Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 10:935-940.
62. Burgert HG, Ruzsics Z, Obermeier S, Hilgendorf A, Windheim M, Elsing A 2002 Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269:273-318.
63. Baker AH 2003 Adenoviral vectors for gene therapy. Mol Biotechnol 25:101-102.
64. Rubanyi GM 2001 The future of human gene therapy. Mol Aspects Med 22:113-142.
65. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG 1999 Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 230:466-470.
66. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH 2003 Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63:7497-7506.
67. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG 1997 Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 8:215-227.
68. Cui L, Li FC, Zhang Q, Qian YL, Guan WX 2003 Effect of adenovirus-mediated gene transfection of vascular endothelial growth factor on survival of random flaps in rats. Chin J Traumatol 6:199-204.
69. Minamide A, Boden SD, Viggeswarapu M, Hair GA, Oliver C, Titus L 2003 Mechanism of bone formation with gene transfer of the cDNA encoding for the intracellular protein LMP-1. J Bone Joint Surg Am 85:1030-1039.
70. Schimandle JH, Boden SD 1994 Spine update. The use of animal models to study spinal fusion. Spine 19:1998-2006.
71. Cheng JC, Guo X, Law LP, Lee KM, Chow DH, Rosier R 2002 How does recombinant human bone morphogenetic protein-4 enhance posterior spinal fusion? Spine 27:467-474.
72. Dimar JR II, Ante WA, Zhang YP, Glassman SD 1996 The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 21:1870-1876.
73. Guizzardi S, Di Silvestre M, Scandroglio R, Ruggeri A, Savini R 1992 Implants of heterologous demineralized bone matrix for induction of posterior spinal fusion in rats. Spine 17:701-707.